CA Patent

CA2744817C — Bile acid recycling inhibitors for treatment of obesity and diabetes

Assigned to Satiogen Pharmaceuticals Inc · Expires 2020-07-07 · 6y expired

What this patent protects

Provided herein are Apical Sodium-dependent Bile Acid Transporter Inhibitors (ASBTIs) for use in the treatment of diabetes in a diabetic individual. The ASBTIs provided herein are non-systemically absorbed ASBTIs that reaches the ileum, colon, and/or rectum of the individual with…

USPTO Abstract

Provided herein are Apical Sodium-dependent Bile Acid Transporter Inhibitors (ASBTIs) for use in the treatment of diabetes in a diabetic individual. The ASBTIs provided herein are non-systemically absorbed ASBTIs that reaches the ileum, colon, and/or rectum of the individual with less than 10% systemic absorption.

Drugs covered by this patent

Patent Metadata

Patent number
CA2744817C
Jurisdiction
CA
Classification
—
Expires
2020-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Satiogen Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.